diabetes   9778

« earlier    

Twitter
RT : Update search for guidelines for the potential update of the type 1 : With the final report, stronger…
DMP  diabetes  from twitter
yesterday by tack48
diaTribe : Making Sense of Diabetes
diaTribe, our patient-focused online publication, is part of The diaTribe Foundation’s mission to improve the lives of people with diabetes. diaTribe seeks to empower our readers with useful, actionable information that gives them hope for a better future, and helps them live happier and healthier lives. Our tag line is “Making Sense of Diabetes.”
diabetes  health  diagnostics  blog  news  medical 
yesterday by cyberchucktx
FreeStyle Libre Now Available in Major US Pharmacies | diaTribe
Two months after approval by the Food and Drug Administration (FDA), Abbott’s FreeStyle Libre (real time) continuous glucose monitor (CGM) is now on the shelves of major pharmacies in the US, including CVS, Walgreens, Walmart, Rite Aid, and Kroger’s/Smith’s. The long awaited sensor finally comes to the US more than three years after it launched in Europe. Here are all the details on how to get one and what it costs.
diabetes  health  cgm  monitor  sugar  diagnostics 
yesterday by cyberchucktx
Dexcom Continuous Glucose Monitoring | Dexcom CGM
Make diabetes treatment decisions with zero fingersticks and no calibration*. Always know where your glucose number is headed with the new Dexcom G6 Continuous Glucose Monitoring (CGM) System.
diabetes  diagnostics  health  dexcom  glucose  monitor  sugar 
yesterday by cyberchucktx
Cardiometabolic Disease Risk in Metabolically Healthy and Unhealthy Obesity: Stability of Metabolic Health Status in Adults
Metabolically healthy obese people are at less risk of T2DM and CVD than metabolically unhealthy thin people.

limitation: may only apply to people 45+

Once again, exercise is the key to health.
fat  research  cvd  diabetes  study 
2 days ago by moose
Eversense CGM
No weekly sensor self-insertions: With Eversense, a trained physician numbs the area and places the sensor in the upper arm and you’re good to go for up to 3-months.

Quickly detects glucose highs and lows: In clinical studies, the Eversense system detected 95% of hypoglycemic episodes (70 mg/dL) and 99% of hyperglycemic episodes (180 mg/dL) within 15 minutes.1

Alerts you can see, feel and hear: The Eversense CGM System can be configured to provide three types of alerts: visual, auditory, and on-body vibe alerts, which can provide you with an additional safety advantage, even during sleep.
diabetes  sensor 
3 days ago by cyberchucktx
50 Shades of Chia Pudding: A Diabetes Breakfast Revolution | diaTribe
What we’ve learned from over 75,000 people about making awesome chia pudding for breakfast: new recipes, new flavors, and how to overcome common stumbling blocks Chia pudding has struck a resounding chord with diaTribe readers: over 40,000 people have viewed the original column, “The Three-Min via Pocket
IFTTT  Pocket  diabetes 
3 days ago by joostw
Twitter
status: awesome
status: in remission
bgnow  t2d  diabetes  from twitter
7 days ago by phoneboy
Glycemic control and vascular complications in type 2 diabetes mellitus - UpToDate
[tl;dr: Glycemic control improves microvascular outcomes in type 2 diabetes, including progression of nephropathy, manifestation and progression of retinopathy, and retinal photocoagulation; and showed a beneficial effect of intensive therapy on the development of more advanced clinical outcomes in renal disease and its precursors in the one study with long-enough follow up to assess effect. Cardiovascular risk benefit "has not been established as clearly" for type 2 as for type 1.]

Although the role of glycemic control on microvascular disease in type 2 diabetes was documented in the United Kingdom Prospective Diabetes Study (UKPDS), its role in reducing cardiovascular risk has not been established as clearly for type 2 diabetes....

improving glycemic control improves microvascular outcomes, as illustrated by the findings of a meta-analysis of randomized trials (34,912 participants) [5]. There was a reduction in the risk of microvascular complications (a composite outcome including progression of nephropathy, manifestation and progression of retinopathy, and retinal photocoagulation) in the intensive compared with standard glycemic control group (relative risk [RR] 0.88, 95% CI 0.82-0.95). There were significant reductions in risk for each of the individual components.

In other meta-analyses of trials (over 28,000 adults) evaluating the benefits of intensive versus conventional glycemic control specifically on renal outcomes, there was a statistically significant reduction in the risk of microalbuminuria and macroalbuminuria in patients randomly assigned to intensive glycemic control (risk ratios of 0.86 and 0.74, respectively) [6,7]. The reduction in risk of end-stage renal disease did not reach statistical significance (RR 0.69, 95% CI 0.46-1.05). There was no reduction in the risk of doubling of the serum creatinine level or death from renal disease (RRs 1.06 and 0.99, respectively) [6]. Of note, the majority of the trials in the meta-analyses were not of long enough duration to show a beneficial effect of glycemic control on end-stage renal disease, which typically manifests after 10 to 20 years of diabetes duration [8]. In the trials included in the meta-analyses, the absolute rates of severe renal outcomes were low in both the intensive- and conventional-therapy groups, reducing the ability of the analysis to demonstrate a benefit, if one exists. In the one trial with longer-term follow-up (United Kingdom Prospective Diabetes Study [UKPDS] cohort followed for 22 years), there was a beneficial effect of intensive therapy on the development of more advanced clinical outcomes, including renal disease
type  2  T2D  diabetes  risk  tight  management  glucose  control  blood  benefit  morbidity  mortality  microvascular  complications  kidneys  eyes  retinopathy  nephropathy  renal  disease  cardiovascular  peer-reviewed  research  review  meta-analysis  overview  in  vivo  situ  human  clinical  trial  symptoms  comorbidities  self  treatment  care 
8 days ago by Michael.Massing
DIY Community Tackles Diabetes | Health Tech Insider
In 2014, there were no commercial systems available that closed the loop between a continuous glucose monitor (CGM) and an insulin pump. For a variety of reasons — including government regulation hurdles — manufacturers were not ready to bring such systems to market. This meant that diabetes patients had to adjust the insulin pump settings based on the readings from the CGM, and often had to rely on traditional finger sticks and even manual injections as well. This can be complicated for adult patients, but can be especially challenging for children who have been diagnosed with Type 1 diabetes.

A woman with Type 1 diabetes and her husband decided to do something about this. They applied the “can do” attitude of the do-it-yourself (DIY) community to solve the problem.
healthtechinsider  diabetes  medical  health  diy  openaps  opensource 
8 days ago by cyberchucktx
Twitter
RT : Great day today. Type 2 reversed, completely medication free as of last week.
A year ago I'd never run.…
diabetes  from twitter
9 days ago by BiteTheDust

« earlier